{"id":4632,"date":"2026-05-12T22:13:00","date_gmt":"2026-05-12T20:13:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=1569e8a466c678a830bc57774f7632ee"},"modified":"2026-05-12T22:13:00","modified_gmt":"2026-05-12T20:13:00","slug":"outcomerx-launches-innovative-targeted-stop-loss-insurance-product-covering-car-t-cell-and-gene-therapies","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=4632","title":{"rendered":"OutcomeRx Launches Innovative Targeted Stop-Loss Insurance Product Covering CAR T-Cell and Gene Therapies"},"content":{"rendered":"

\nCGT Solutions Stop-Loss covers treatment costs of up to $4.5M for self-funded employers nationwide<\/i><\/p><\/a><\/a>

ORLANDO, Fla.--(BUSINESS WIRE)--OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss<\/b>, a stand-alone medical stop-loss insurance product that reimburses covered expenses on qualified claims for Gene and CAR T-cell therapies for group health plans and their coordinating Stop-Loss carrier. This innovative solution, in addition to reimbursement for certain FDA approved Prescription Drugs, uniquely reimburses administration of the Prescription Drug and travel-related expenses for the family and patient. The product is underwritten by Fidelity Security Life Insurance Company\u00ae (FSL), an A.M. Best A Rated (Excellent) company.<\/p>

\nEmployers also receive access to value-add services including patient care navigation and a network of 100+ Centers of Excellence.<\/p>

\n\u201cCell and gene therapies can deliver life-changing outcomes for patients, but the financial exposure for self-insured plans is unprecedented,\u201d said Joe Morse, CEO of OutcomeRx Insurance Management Services, LLC. \u201cCGT Solutions Stop-Loss insurance supports our mission to provide affordable access for patients to receive these life-changing therapies.\u201d<\/p>

\nBryce Jones, President of FSL commented, \u201cTraditional stop-loss models were not designed for the scale and unpredictability of multi-million-dollar gene therapy claims. This product uniquely provides protection that is essential for plan stability.\u201d<\/p>

\nCGT Solutions Stop-Loss Insurance <\/b>This stop-loss insurance integrates with an Employer\u2019s existing healthcare offering covering gene and CAR T-cell therapies for qualified claims. This new product adds to OutcomeRx\u2019s existing portfolio of reinsurance solutions.<\/p>

\nStop-loss coverage is available to self-funded employers through licensed brokers and consultants.<\/p>

\nAbout OutcomeRx Insurance Management Services, LLC<\/b><\/p>

\nOutcomeRx is a specialty insurance management organization focused on innovative risk solutions that support affordable access to high-value therapies for self-funded employers.<\/p>

\nAbout Fidelity Security Life Insurance Company<\/b><\/p>

\nFidelity Security Life Insurance Company is a Kansas City, Missouri-based insurance carrier providing a broad portfolio of life and health insurance products nationwide.<\/p> Contacts<\/b>

\nMedia Contact:<\/b>OutcomeRx Insurance Management Services, LLC\nLarry Bailey\n(475) 205-2100\nlarry.bailey@outcomerx.com<\/a>www.outcomerx.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"

CGT Solutions Stop-Loss covers treatment costs of up to $4.5M for self-funded employers nationwideORLANDO, Fla.–(BUSINESS WIRE)–OutcomeRx Insurance Management Services, LLC today announced the launch of CGT Solutions Stop-Loss, a stand-alone medical…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-4632","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4632"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4632\/revisions"}],"predecessor-version":[{"id":4633,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/4632\/revisions\/4633"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4632"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}